NCT00442871View on ClinicalTrials.gov

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

September 28, 2006

Primary Completion Date

January 3, 2008

Study Completion Date

January 3, 2008

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG

eltrombopag

eltrombopag 50 mg oral

Trial Locations (2)

32608

GSK Investigational Site, Gainesville

55114-1067

GSK Investigational Site, Saint Paul

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY